透景生命(300642.SZ)拟取得康录生物控股权 追求协同效应

Core Viewpoint - The company intends to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd., which will become a subsidiary and included in the company's consolidated financial statements after the acquisition is completed [1][2] Group 1: Acquisition Details - The transaction amount for acquiring 72.8630% of Kanglu Biological is RMB 291 million [1] - If certain conditions are met in 2026 and 2027, the company plans to acquire an additional 9.1370% of Kanglu Biological from Chen Gang and Xie Jun, with a transaction amount of RMB 36.5481 million based on asset valuation reports [1] Group 2: Business and Strategic Implications - Kanglu Biological focuses on the fluorescence in situ hybridization (FISH) and PCR molecular diagnostics fields, aiming for rapid, automated, and intelligent solutions [2] - The company has developed and sold rapid FISH reagents and automated detection equipment, holding proprietary technology for FastProbe® rapid FISH probe preparation [2] - The acquisition is expected to create synergies in development strategy, market channels, products, and technology, enhancing the company's overall competitiveness and providing new revenue and profit growth opportunities [2]